Skip to content

Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells

Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00801372
Enrollment
1
Registered
2008-12-03
Start date
2008-11-30
Completion date
2030-12-31
Last updated
2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Male Newborns, Pregnant, Healthy Females

Keywords

termination of pregnancy, surgical circumcision, umbilical cord

Brief summary

Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation. The major goal of the project is to develop human iPS cells from existing lines of fibroblasts that were originally donated as clinical grade feeders for the development of clinical grade hESCs. The clinical grade feeders were developed from aborted fetuses, foreskin and umbilical cord.

Detailed description

The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc. The clinical grade donated feeders used in this project were developed under GMP conditions using animal-free reagents. For potential future clinical applications, the iPS cells will be developed under GMP conditions, using reagents and methods that will be acceptable for clinical applications.

Interventions

None listed

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* healthy, older than 18

Exclusion criteria

* non healthy, younger than 18

Countries

Israel

Contacts

Primary ContactBenjamin E Reubinoff, MD PhD
benjaminr@ekmd.huji.ac.il011-972-2-6774569
Backup ContactShelly E. Tannenbaum, MSQA
stannenbaum@hadassah.org.il011-972-2-572-2000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026